Combined with previous liver cancer immune cycle results, this evidence demonstrates that anti-Tim-3 therapy may achieve stronger anti-tumor effects by acting on both intrinsic malignant cells and immune cells, further supporting its potential as a targeted therapeutic marker. The gene discussed is HAVCR2; the disease is liver cancer.